Full Text View
Tabular View
No Study Results Posted
Related Studies
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
This study has been completed.
Study NCT00054418   Information provided by National Cancer Institute (NCI)
First Received: February 5, 2003   Last Updated: May 12, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Osteoporosis
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Breast Diseases
Musculoskeletal Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
calcium carbonate
cholecalciferol
risedronate sodium
Additional drug interventions recognized in this trial
Risedronic acid
More general drug interventions related to this trial
Antacids
Bone Density Conservation Agents
Calcium Channel Blockers
Cardiovascular Agents
Growth Substances
Membrane Transport Modulators
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vitamins
Sponsors listed in this trial
North Central Cancer Treatment Group
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services